GentiBio

GentiBio is growing! Genti's CMO, Mark Bach, is looking for a talented individual to join the Clinical Operations team! This is a key leadership role, with the opportunity to establish clinical operations practices, ensure regulatory compliance, and oversee clinical Contract Research Organization activities, and more. Come join us in making a meaningful difference in the lives of our patients! #autoimmunediseases #T1D #gentibio #biotechjobs #clinicaloperations

The GentiBio #team enjoyed partaking in the Breakthrough T1D Walk in Boston last week! We walked to raise money for Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization. We are honored to work for an organization that is focusing on ways to better treat and potentially cure patients with T1D.  

We are pleased to introduce Mark Bach as Chief Medical Officer at GentiBio! In this role, Dr. Bach will oversee clinical development and lead clinical strategy for GentiBio’s engineered regulatory T-cell (Treg) therapeutics for the treatment of autoimmune and inflammatory conditions. Mark brings over 30 years of experience in clinical research and development from biopharmaceutical companies including Structure, Ascendis Pharma, Janssen/Johnson & Johnson, and Merck. Read more about it here: https://lnkd.in/gCg8QBex

GentiBio representing at Boston’s Breakthrough T1D Walk! Finding a cure of Type 1 Diabetes together.

GentiBio's Chief Scientific Officer, Thomas Wickham, is presenting at the 9th CAR-TCR Summit in Boston, MA today on “Moving Beyond Oncology: The Opportunity of Autoimmune Diseases.”   While cell therapies for cancer have seen significant breakthroughs, their application in treating autoimmune diseases is showing great potential. Early results show promise in modulating or suppressing the immune response and preventing the immune system from attacking the body’s own tissues. Ongoing research is rapidly advancing, and there is optimism that these therapies will deliver safe, effective, and long-term solutions for managing and potentially curing autoimmune conditions. #biotech #autoimmunediseases

During the month of July, the Genti team facilitated workshops focused on communication & leadership. Both sites came together to learn more about the RACI model to implement on our cross-functional project teams. This session was driven by our very own Genti team members, who exemplified one of our core values, 'the courage to use your voice'. They have a passion for integrating workshops into our culture and we appreciate all that they do! We also had the opportunity to listen and learn from Andy Walker, COO & President, and Tom Wickham, CSO, on their leaderships styles and leading through change. Effective leaders inspire, influence and encourage their team by investing in a shared vision, leading with authenticity according to their values and demonstrating resilience through setbacks or challenges. With the support and drive of our impressive leaders, the Genti team is thriving and primed for success.

Over the past few weeks, the GentiBio #team came together to celebrate our organization’s 4-year anniversary! The Cambridge office joined together for a summer picnic and the Seattle office went on a sailing excursion! In honor of one of our core values, “we care for each other so we may care for our communities and patients”, we recharged by engaging in adventures with our colleagues! For Genti’s birthday, we want to say how thankful we are for our team. You all make Genti a wonderful place to work, and each of you contribute to our mission, community, and culture. Happy 4th Birthday Genti! 

Alberto del Río Espínola, PhD, Director, Translational Sciences here at GentiBio recently attended the Gene Therapy Development 2024 Conference in London, UK! He presented “Advancements in ex vivo gene editing for T-cells: tailored Treg therapies” and joined in as a speaker on a genome editing strategy discussion. Way to go, Alberto!

Last week, Payam Zarin, Associate Director and Research lead from GentiBio presented on “A Tissue Engineered Treg Approach for the Treatment of Acute Ischemic and Inflammatory Diseases” at the Gordon Immunochemistry and Immunobiology Conference in Maine. The premier international scientific conference concentrates on the latest developments in immunology and GentiBio is excited to be sharing new data supporting our Engineered T-Regulatory cell therapy modalities and indications. #Tregs #biotech

At last week's 6th Annual Symposium of the Food Allergy Science Initiative hosted by the Broad Institute in Cambridge, Madison Milaszewski, a #Scientist in our Discovery group at GentiBio, presented on some of Genti’s exciting pre-clinical data highlighting efficacy of Engineered Tregs in a model of acute lung injury! Way to go, Madison! #Tregs #biotech